<DOC>
	<DOCNO>NCT01867866</DOCNO>
	<brief_summary>The purpose study compare pharmacokinetics trifluorothymidine ( FTD ) component TAS-102 FTD alone .</brief_summary>
	<brief_title>Study Comparing Pharmacokinetics FTD Component TAS-102 With FTD Alone</brief_title>
	<detailed_description>This Phase 1 , open-label , randomize , parallel , 2-group study evaluate PK FTD TAS-102 component compare FTD alone patient advance solid tumor ( exclude breast cancer ) . Patients randomize receive single dose TAS-102 FTD PK contribution phase receive continue cycle TAS-102 extension phase .</detailed_description>
	<mesh_term>Trifluridine</mesh_term>
	<criteria>1 . Has provide write informed consent 2 . Has advance solid tumor ( exclude breast cancer ) standard therapy exist 3 . ECOG performance status 0 1 4 . Is able take medication orally 5 . Has adequate organ function ( bone marrow , kidney liver ) 6 . Women childbearing potential must negative pregnancy test must agree adequate birth control conception possible . Males must agree adequate birth control . 1 . Has certain recent treatment e.g . anticancer therapy , receive investigational agent , within specified time frame prior study drug administration 2 . Certain serious illness medical condition ( ) 3 . Has either partial total gastrectomy 4 . Has unresolved toxicity great equal CTCAE Grade 2 attribute prior therapy 5 . Known sensitivity TAS102 components 6 . Is pregnant lactate female 7 . Refuses use adequate mean contraception ( include male patient )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Advanced solid tumor ( exclude breast cancer ) standard therapy exists</keyword>
</DOC>